Morgan Stanley Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $124.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target upped by equities researchers at Morgan Stanley from $119.00 to $124.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would suggest a potential upside of 96.17% from the company’s current price.

Several other equities research analysts also recently commented on BMRN. Oppenheimer boosted their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings raised shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 26th. UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Canaccord Genuity Group decreased their price objective on BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Finally, Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $87.86.

BioMarin Pharmaceutical Stock Up 2.8%

Shares of BMRN traded up $1.75 during trading hours on Friday, reaching $63.21. The stock had a trading volume of 2,999,250 shares, compared to its average volume of 2,050,135. The firm has a 50-day simple moving average of $58.06 and a 200 day simple moving average of $57.01. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $66.28. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $12.22 billion, a price-to-earnings ratio of 46.06, a P/E/G ratio of 0.46 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 8.29% and a return on equity of 6.50%. The business had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same quarter in the previous year, the business posted $1.44 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts predict that BioMarin Pharmaceutical will post 4.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Hedge funds have recently modified their holdings of the company. Pallas Capital Advisors LLC purchased a new position in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $397,000. Deutsche Bank AG bought a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $7,226,000. Rice Hall James & Associates LLC purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $14,203,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $39,000. Finally, Monaco Asset Management SAM bought a new stake in BioMarin Pharmaceutical during the second quarter worth $10,582,000. Institutional investors own 98.71% of the company’s stock.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations: BioMarin reported adjusted earnings of $1.20 per share, above the roughly $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, surpassing estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: The company now expects full-year adjusted EPS of $4.90–$5.10, above the prior consensus estimate of $4.80. Revenue guidance was set at approximately $3.9 billion, broadly in line with expectations. BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
• Positive Sentiment: Growth initiatives strengthened the longer-term outlook: Management highlighted continued momentum for VOXZOGO and the addition of Amicus products GALAFOLD and POMBILITI plus OPFOLDA. Expected cost synergies are projected to support revenue growth, earnings accretion, operating-margin expansion, and cash flow through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Although earnings beat estimates, quarterly EPS declined from $1.44 in the prior-year period, making the improved revenue trend and raised guidance important to sustaining investor enthusiasm. BioMarin Earnings Results and Conference Call
• Negative Sentiment: HC Wainwright raised its price target to $60 from $50 but retained a neutral rating. The new target remains below the stock’s recent trading level, signaling valuation concerns and limiting the strength of the analyst endorsement. Benzinga Analyst Rating Update

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.